The assessment of the new immune gene signature (CD2, CD3D, CD3E, and CXCRC6) in the CSCC cohort per tumor stage was not possible because sample size was too low for a meaningful analysis when we filtered data by stage. This evidence concerns the gene CD3E and neoplasm.